SeaStar Medical Q2 net loss $3.2M; first commercial QUELIMMUNE sales in July

SeaStar Medical Holding Corp

2024-Q2 EPS reported -$5.36

Net loss $3.2M ($1.03/share) vs $2.4M ($4.10/share) in Q2 2023, driven by higher R&D and G&A.
First commercial sales of QUELIMMUNE for pediatric AKI in July 2024; launched with U.S. distribution partner.
Adult NEUTRALIZE-AKI trial enrolled 42 subjects at 9 sites; CMS granted Category B coverage for Medicare/Medicaid.
Completed $10M registered direct offering in July; cash ~$6.9M as of July 31 after reducing debt by $2.7M.
Board expanded with three new directors; expects adult PMA approval in H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.